StockNews.com started coverage on shares of CASI Pharmaceuticals (NASDAQ:CASI – Free Report) in a research report sent to investors on Friday morning. The brokerage issued a hold rating on the biotechnology company’s stock.
Separately, HC Wainwright dropped their price target on shares of CASI Pharmaceuticals from $12.00 to $6.00 and set a buy rating for the company in a research note on Wednesday, May 15th.
Read Our Latest Research Report on CASI
CASI Pharmaceuticals Trading Down 0.5 %
CASI Pharmaceuticals (NASDAQ:CASI – Get Free Report) last posted its earnings results on Tuesday, May 14th. The biotechnology company reported ($0.71) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.66). CASI Pharmaceuticals had a negative return on equity of 110.11% and a negative net margin of 105.76%. The firm had revenue of $3.41 million for the quarter. Equities research analysts predict that CASI Pharmaceuticals will post -2.56 EPS for the current fiscal year.
Institutional Trading of CASI Pharmaceuticals
A hedge fund recently bought a new stake in CASI Pharmaceuticals stock. Howland Capital Management LLC purchased a new position in CASI Pharmaceuticals, Inc. (NASDAQ:CASI – Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 40,429 shares of the biotechnology company’s stock, valued at approximately $146,000. Howland Capital Management LLC owned about 0.30% of CASI Pharmaceuticals at the end of the most recent quarter. 22.23% of the stock is currently owned by institutional investors.
About CASI Pharmaceuticals
CASI Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma.
See Also
- Five stocks we like better than CASI Pharmaceuticals
- What Are Trending Stocks? Trending Stocks Explained
- Is Crypto Cool Again? What Stocks You Should Be Watching
- Financial Services Stocks Investing
- Why Call Options Volume for These 2 Stocks Spiked Together
- Are Penny Stocks a Good Fit for Your Portfolio?
- MarketBeat Week in Review – 7/22 – 7/26
Receive News & Ratings for CASI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.